The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Potassium Chloride
Potassium Chloride · POTASSIUM CHLORIDE 149 mg/mL · Injection, Solution, Concentrate · Intravenous · HF Acquisition Co LLC, DBA HealthFirst
NDC 51662-1421-01 · 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00409-6653-05) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.1942per unit
middle half $0.1758–$0.2330 · 5,179 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.1942
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
94%of plans cover it
tier 4 · prior auth 1% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- HF Acquisition Co LLCUnited Statesrelabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $24.12 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Xywav and Xyrem
Regulatory
- Application
- ANDA080205
- TE code
- AP
- Approval date
- Jan 1, 1982
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Potassium Chloride (Injection, Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Hospira, Inc. | POTASSIUM CHLORIDE 149 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| B. Braun Medical Inc. | POTASSIUM CHLORIDE 14.9 g/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Henry Schein, Inc. | POTASSIUM CHLORIDE 149 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Henry Schein, Inc. | POTASSIUM CHLORIDE 2 meq/mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | POTASSIUM CHLORIDE 2 meq/mL | Jul 15, 2026 | Aug 31, 2026 |
| HF Acquisition Co LLC, DBA HealthFirst | POTASSIUM CHLORIDE 149 mg/mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Potassium Chloride — NDC 51662-1421-01," retrieved September 3, 2026, https://drugdashboards.com/drug/51662142101.
Free to cite with attribution — see how the data is put together.